PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-12-09

Date Title Company
09-Dec-2025 World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis Businesswire
09-Dec-2025 A glass of red wine this Christmas could be good for you, says expert. It’s ‘The French Paradox’! Sinclair Method UK
09-Dec-2025 Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology Oncoinvent
09-Dec-2025 Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS) Newron
09-Dec-2025 PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis PureTech
09-Dec-2025 Poolbeg Pharma plc - POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg Pharma
09-Dec-2025 SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate SeaBeLife
09-Dec-2025 Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer Pan Cancer T
09-Dec-2025 RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations Johnson & Johnson
09-Dec-2025 Senzime secures major TetraGraph order from leading UK NHS hospital system Senzime
09-Dec-2025 Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome Fibrocor Therapeutics
09-Dec-2025 Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma J&J
09-Dec-2025 Chiesi Marks Key Net Zero Milestone with its First Carbon Minimal pMDI Product Submission to the MHRA for Clenil® Modulite® (beclometasone) Chiesi
09-Dec-2025 AFYREN and ESSE Skincare Begin Partnership to Offer 100% Natural Cosmetic Solutions With Enhanced Skincare Performance Businesswire
09-Dec-2025 Pressure Monitoring Market Size and Share Forecast Outlook From 2025 to 2030 Medi-Tech Insights
09-Dec-2025 Microplate Systems Market Is Booming So Rapidly| Thermo Fisher Scientific; Danaher Corporation; Agilent Technologies Inc; PerkinElmer Inc Medi-Tech Insights
09-Dec-2025 Intravenous (IV) Fluid Bags Market 2025-2030 | Key Trends, Opportunities, and Growth Factors in New Report Medi-Tech Insights
09-Dec-2025 Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 ACCESS Newswire
09-Dec-2025 Vheda Health Named a 2025 Top Workplace in Metro Area by the Baltimore Sun ACCESS Newswire
09-Dec-2025 Hememics' Graphene-Based ESAP(TM) Platform Validated by KanPro Research, Securing Commercial Trial Order ACCESS Newswire